TMED7-TICAM2: A Potential Drug Target and Biomarker (G100302736)

Target Name: TMED7-TICAM2

NCBI ID: G100302736

TMED7-TICAM2

TMED7-TICAM2: A Potential Drug Target and Biomarker

Telomere-associated extended-sense DNA methylation (TMES-DNAm) has been identified as a promising strategy for targeting the regulation of aging and age-related diseases. TMES-DNAm is a epigenetic modification that involves the reversible addition of methyl groups to the ends of telomeres, which are repetitive DNA sequences that protect the ends of chromosomes from degradation and fusion. In recent years, TMES-DNAm has been shown to play a crucial role in a wide range of biological processes, including aging, DNA repair, and cellular signaling.

One potential drug target for TMES-DNAm is TMED7-TICAM2, a protein that is expressed in a variety of tissues and cells and is involved in the regulation of telomere length. TMED7-TICAM2 has been shown to interact with the DNA methylation complex, which includes the protein TP53, and is involved in the reversible addition of methyl groups to the ends of telomeres. This interaction between TMED7-TICAM2 and TP53 suggests that TMED7-TICAM2 may be a useful drug target for TMES-DNAm.

In addition to its role in TMES-DNAm, TMED7-TICAM2 is also a potential biomarker for a variety of age-related diseases. As telomeres are a component of the aging process, the length of telomeres can serve as a useful indicator of an individual's age and the potential for age-related diseases. For example, shorter telomeres have been associated with an increased risk of certain age-related diseases, including cancer and cardiovascular disease. By targeting TMED7-TICAM2, a drug that can extend telomeres may have potential therapeutic applications for a variety of age-related diseases.

The structure and function of TMED7-TICAM2 are of great interest for drug development. TMED7-TICAM2 is a 21-kDa protein that is expressed in a variety of tissues and cells, including brain, heart, and liver. It is composed of a N-terminus, a middle domain, and an C-terminus. The N-terminus of TMED7-TICAM2 contains a putative transmembrane domain and is involved in the protein's localization to the endoplasmic reticulum (ER) and the nuclear envelope (NE). The middle domain of TMED7-TICAM2 contains a number of potential binding sites, including interaction with DNA methylation complexes. The C-terminus of TMED7-TICAM2 contains a single amino acid residue that is involved in the protein's stability and may be involved in its intracellular localization.

To study the function of TMED7-TICAM2, researchers have used a variety of techniques, including biochemical, cellular, and biomechanical assays. For example, researchers have shown that TMED7-TICAM2 is involved in the regulation of telomere length and that it interacts with the DNA methylation complex. They have also used RNAi screening to identify potential binding sites in the middle domain of TMED7-TICAM2 and used in vitro assays to study the protein's stability and localization to the ER and NE.

While the potential drug target for TMED7-TICAM2 is still being explored, its potential as a biomarker for age-related diseases is already a promising area of research. TMED7-TICAM2 may be a useful biomarker for assessing the effectiveness of drugs that target TMES-DNAm, as well as for identifying potential therapeutic approaches for

Protein Name: TMED7-TICAM2 Readthrough

Functions: Potential role in vesicular protein trafficking, mainly in the early secretory pathway. Appears to play a role in the biosynthesis of secreted cargo including processing and post-translational modifications

The "TMED7-TICAM2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMED7-TICAM2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets